Company Overview
Instil Bio is a biotechnology firm focused on advancing innovative therapeutics. The company recently discontinued the clinical development of AXN-2510. Moving forward, Instil Bio will focus its capital on pursuing potential acquisitions and in-licensing opportunities to build a differentiated pipeline.
Key Financial Figures
For the full year ended December 31, 2025, Instil Bio reported a basic and diluted net loss per share (EPS) of $10.70, while the fourth quarter net loss per share was $1.21. The provided financial statements do not report any product revenue for these periods.
Additional Financial Insights
Instil Bio concluded 2025 with $76.3 million in total cash, cash equivalents, restricted cash, and marketable securities. The company anticipates that these capital resources will be sufficient to fund its current operating plan beyond the year 2027.
The post Instil Bio Q4 and Full Year 2025 Financial Review first appeared on Alphastreet.
